Draft:Horst Sievert

  • Comment: I think you have probably written what you wish to say about the subject, and then sought references after writing in order to cite what you say. This is WP:BACKWARDS. Instead, please read this essay, one of several which outline a process which will succeed assuming the subject to be notable. If it isn't notable then no amount of editing can help. We use the references in the process described in the essay to determine and verify notability. No suitable references means the subject is not notable, and it is time to stop.
    For a living person we have a high standard of referencing. Every substantive fact you assert, especially one that is susceptible to potential challenge, requires a citation with a reference that is about them, and is independent of them, in multiple secondary sources which are WP:RS, and is significant coverage. Please also see WP:PRIMARY which details the limited permitted usage of primary sources and WP:SELFPUB which has clear limitations on self published sources. Providing sufficient references, ideally one per fact cited, that meet these tough criteria is likely to make this draft a clear acceptance (0.9 probability). Lack of them or an inability to find them is likely to mean that the person is not suitable for inclusion, certainly today. 🇵🇸‍🇺🇦 FiddleTimtrent FaddleTalk to me 🇺🇦‍🇵🇸 23:40, 19 February 2026 (UTC)

COI disclosure

Disclosure: I am Horst Sievert, the subject of this draft. To avoid conflict of interest issues, I have prepared this draft with careful attention to neutrality and reliable sourcing.

The article text is based on independent, verifiable sources (peer-reviewed journals, professional society websites, and independent faculty profiles). Promotional language has been avoided, and all claims are supported by citations.

I kindly ask experienced reviewers to evaluate this draft for compliance with Wikipedia’s notability and BLP (Biographies of Living Persons) standards. Thank you for your time and support.

Horst Sievert
Horst Sievert (2025)
Born1954 (age 71–72)
Known forStructural heart interventions; transcatheter valve therapies; PFO/LAA closure; peripheral vascular interventions; renal denervation
AwardsTCT Master Operator Award (2011); PICS Achievement Award (2011)

Horst Sievert (born 1954) is a German interventional cardiologist based in Frankfurt am Main. He is the founder and director of the CardioVascular Center Frankfurt (CVC). Sievert is recognized internationally for his contributions to structural heart disease interventions, coronary and peripheral vascular procedures, transcatheter valve therapies, and minimally invasive catheter-based cardiovascular treatments.[1][2]

Career

Sievert began his career as chief of the Department of Interventional Cardiology and Angiology at the Herz- und Kreislaufzentrum Rotenburg an der Fulda in 1990, one of Germany’s largest centers for interventional cardiology.[3] In 1993, he joined the Cardioangiologisches Centrum Bethanien (CCB) in Frankfurt.[4] He founded the CardioVascular Center Frankfurt (CVC) in 2003 and remains its director.[5] From 2006 to 2009, Sievert held a part-time clinical appointment at Washington Hospital Center in Washington, DC.[6] Between 2012 and 2014, he was involved in the early clinical implementation of transcatheter aortic valve replacement (TAVR) in mainland China.[7]

Research and clinical contributions

Sievert's expertise encompasses:

  • Coronary interventions (PCI).
  • Structural heart disease: closure of patent foramen ovale (PFO), atrial septal defect (ASD), left atrial appendage (LAA), and transcatheter valve therapies including TAVR, TMVR, TTVR.
  • Peripheral vascular interventions including percutaneous transluminal angioplasty (PTA) and carotid stenting.
  • Acute stroke therapies, with participation in multicenter trials on carotid stenting and embolic protection devices.[8]
  • Device-based therapies like renal denervation, notably in the SYMPLICITY HTN-2 trial.[9]

He was one of the international investigators in the first Chinese TAVR clinical trial program.[10]

Sievert has been principal investigator in several multicentre clinical trials, including PROTECT AF, EWOLUTION, Amulet IDE, CHAMPION AF, LAAOS-4, CoreValve ADVANCE, BioVentrix Revivent, and CORCINCH.[11]

He has also advanced device-free and bioresorbable occlusion approaches, including the radiofrequency-mediated PFO closure (PARADIGM study) and evaluation of fully biodegradable occluders.[12][13]

He has contributed to key international consensus statements on left atrial appendage occlusion, patent foramen ovale closure, and peripheral artery disease.[14]

Conferences and education

Sievert founded and directs the annual CSI conference series held in Frankfurt, and co-directs the ICCA Stroke course. He co-founded the WIST Foundation, promoting international collaboration in stroke therapy.[15] He extended CSI conferences to Asia-Pacific and Africa to support training in structural and valvular heart interventions.[16]

Professional leadership

Sievert has served on the Executive Board of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) as Treasurer. He is faculty at multiple major international conferences, including TCT, EuroPCR, AHA Scientific Sessions, ACC, SCAI Scientific Sessions, and the DGK Congress.[17]

Awards and recognition

  • TCT Geoffrey O. Hartzler Master Clinical Operator Award (2011).[18][19]
  • PICS Achievement Award (2011).[20]
  • Highly Cited Researcher (Clarivate/Web of Science, 2020).[21]

Selected publications

  • Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion in atrial fibrillation: early experience. J Am Coll Cardiol. 2002;39:2094–2099.
  • Sievert H, et al. Transcatheter closure of patent foramen ovale after cryptogenic stroke. Circulation. 2001;103:947–953.
  • Holmes DR, Reddy VY, Sievert H, et al. Percutaneous closure of the left atrial appendage versus warfarin for atrial fibrillation. Lancet. 2009;374:534–542.
  • Reddy VY, Sievert H, Halperin J, et al. Percutaneous LAA closure vs warfarin for AF: randomized clinical trial. JAMA. 2014;312:1988–1998.
  • Esler M, Krum H, Sievert H, et al. Renal sympathetic denervation in resistant hypertension (SYMPLICITY HTN-2). Lancet. 2010;376:1903–1909.

References

  1. ^ "Prof. Dr. Horst Sievert – CVC Frankfurt Team". CVC Frankfurt. Retrieved 21 February 2025.
  2. ^ "Horst Sievert Profile". Radcliffe Cardiology. Retrieved 27 September 2025.
  3. ^ "Prof. Dr. Horst Sievert – CVC Frankfurt Team". CVC Frankfurt. Retrieved 21 February 2025.
  4. ^ Sievert, H (2012). "Transcatheter closure of patent foramen ovale using the Figulla device". EuroIntervention. 8: 609–615. doi:10.4244/EIJV8I5A96.
  5. ^ "Prof. Dr. Horst Sievert – PCRonline Faculty". EuroPCR. Retrieved 21 February 2025.
  6. ^ Sievert, H (2007). "Percutaneous closure of the left atrial appendage in patients with atrial fibrillation". Circulation. 116: 447–454. doi:10.1161/CIRCULATIONAHA.106.686915.
  7. ^ "Venus Medtech History". Venus Medtech. Retrieved 21 February 2025.
  8. ^ Clinical Trials at CVC Frankfurt – Status February 2025 (Report). CVC Frankfurt. 17 February 2025.
  9. ^ Esler, M; Krum, H; Sievert, H (2010). "Renal sympathetic denervation in patients with hypertension (SYMPLICITY HTN-2 trial)". Lancet. 376: 1903–1909. doi:10.1016/S0140-6736(10)62039-9.
  10. ^ Zhou, D; Sievert, H (2015). "Transcatheter aortic valve implantation in China: first multicentre trial". Catheterization and Cardiovascular Interventions. 85: 920–927. doi:10.1002/ccd.25874.
  11. ^ Clinical Trials at CVC Frankfurt – Status February 2025 (Report). CVC Frankfurt. 17 February 2025.
  12. ^ Sievert, H (2007). "Transcatheter closure of patent foramen ovale without an implant: initial clinical experience (PARADIGM study)". Circulation. 116: 1701–1706. doi:10.1161/CIRCULATIONAHA.107.709444.
  13. ^ "World's First Absorbable PFO Occluder in Action – Live from CSI Frankfurt". Lepu Medical. Retrieved 22 September 2025.
  14. ^ Glikson, M (2020). "EHRA/EAPCI consensus statement on catheter-based left atrial appendage occlusion". EuroIntervention. 15: 1133–1180. doi:10.4244/EIJY19M08_01.
  15. ^ "WIST Foundation – About". WIST Foundation. Retrieved 22 September 2025.
  16. ^ "CSI Africa". CSI Congress. Retrieved 22 September 2025.
  17. ^ "EAPCI Executive Board 2010–2012". EuroIntervention. 7: 103–105. 2011. doi:10.4244/EIJV7I1A18.
  18. ^ "Master Operator Award". TCT Conference. Retrieved 25 September 2025.
  19. ^ "Horst Sievert, MD, PhD, presented with Master Clinical Operator Award". ScienceX. 8 November 2011. Retrieved 27 September 2025.
  20. ^ "PICS Achievement Award – 2011: Horst Sievert". PICS Society. Retrieved 22 September 2025.
  21. ^ "Highly Cited Researchers 2020". Web of Science. Retrieved 27 September 2025.

Category:Living people Category:1954 births Category:German cardiologists Category:Interventional cardiology

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.